Dermatol Surg. 2025 Mar 4. doi: 10.1097/DSS.0000000000004609. Online ahead of print.
NO ABSTRACT
PMID:40035721 | DOI:10.1097/DSS.0000000000004609
Hyperhidrosis, anticholinergics, and dementia
Actas Dermosifiliogr. 2025 Feb 28:S0001-7310(25)00110-3. doi: 10.1016/j.ad.2024.11.026. Online ahead of print.
ABSTRACT
In recent decades, the use of certain oral anticholinergics for the treatment of hyperhidrosis has become widespread, often off-label but supported by multiple studies, including clinical trials, demonstrating their effectiveness and an apparently good safety profile. Similarly, various studies published in recent years have associated the use of anticholinergics to the development of dementia, particularly in elderly patients. Additionally, other studies have suggested that hyperhidrosis itself may be an early symptom of developing dementia. However, to date, no research has specifically linked the use of oral anticholinergics for hyperhidrosis treatment with the development of dementia. We present the currently available data on this controversial topic.
PMID:40024600 | DOI:10.1016/j.ad.2024.11.026
Topical oxybutynin deodorant for axillary hyperhidrosis: a topic or a systemic effect? Rationale and design of the phase II today trial
J Vasc Bras. 2025 Feb 21;24:e20240098. doi: 10.1590/1677-5449.202400982. eCollection 2025.
ABSTRACT
Anticholinergics have been shown to enhance quality of life and reduce sweat in patients with hyperhidrosis. However, it remains unclear whether topical application specifically exerts local or systemic effects. This study’s primary aim is to assess topical oxybutynin’s impact on axillary hyperhidrosis. Twenty patients will be randomized into three groups. Group A will receive 2.5 mg of oral oxybutynin from day 1 to day 35 (on a variable frequency regimen). Group B will be administered a topical placebo for 35 days and Group C will receive a 10% oxybutynin topical spray, to be used twice daily for 35 days. The primary efficacy outcome will be the evaluation of the effectiveness of topical oxybutynin spray in treating hyperhidrosis. The TODAY trial will generate high-quality evidence on the effects of topical oxybutynin, assessing whether its impact is local or systemic in patients with axillary hyperhidrosis.
PMID:40012967 | PMC:PMC11864779 | DOI:10.1590/1677-5449.202400982
Arabic Translation, Cultural Adaptation, and Validation of the Hyperhidrosis Disease Severity Scale (Ar-HDSS)
Healthcare (Basel). 2025 Feb 12;13(4):397. doi: 10.3390/healthcare13040397.
ABSTRACT
Background: Hyperhidrosis (HH) is characterized by excessive sweating, which affects quality of life. The Hyperhidrosis Disease Severity Scale (HDSS) is a four-point scale used to evaluate HH severity by measuring how much excessive sweating disrupts daily activities. This study aimed to translate, validate, and adapt the HDSS tool into Arabic. Methods: A quantitative, analytical, cross-sectional study was carried out from May to June 2024 on patients clinically diagnosed with HH. The process of translating the HDSS into Arabic involved three independent forward translations, followed by a preliminary version created by a reviewer. Three additional independent translators conducted backward translations. All of the versions were then revised and merged to produce the final version. Reliability was evaluated through a test-retest reliability approach to ensure the reproducibility of the results. For validity, we used construct validity to compare the HDSS with the HidroQoL index. Results: A total of 167 patients were included, with a mean age of 29 ± 9.02 years, and over half of the patients were male (61%). The interrater agreement between the HDSS test and the retest results was substantial, with a kappa coefficient of 0.732. Significant positive correlations were observed between the HDSS score and daily life (r = 0.413, p < 0.001), the psychological domain (r = 0.374, p < 0.001), and HidroQOL (r = 0.425, p < 0.001). Conclusions: Our findings demonstrate that the Arabic HDSS has excellent psychometric properties, including construct validity and reproducibility. Proper use of the Arabic HDSS will allow the effective assessment of HH severity.
PMID:39997272 | DOI:10.3390/healthcare13040397
Hyperhidrosis after COVID-19 infection
Arch Dermatol Res. 2025 Feb 22;317(1):457. doi: 10.1007/s00403-025-03992-8.
NO ABSTRACT
PMID:39987360 | DOI:10.1007/s00403-025-03992-8
UNILATERAL HYPERHIDROSIS. SYMPTOM OF THORACIC OUTLET SYNDROME: 2-CASE REVIEW
Actas Dermosifiliogr. 2025 Feb 11:S0001-7310(25)00067-5. doi: 10.1016/j.ad.2023.10.057. Online ahead of print.
NO ABSTRACT
PMID:39947590 | DOI:10.1016/j.ad.2023.10.057
Switching to levomethadone improves methadone-induced hyperhidrosis: A case report
J Addict Dis. 2025 Feb 5:1-5. doi: 10.1080/10550887.2024.2443696. Online ahead of print.
ABSTRACT
Methadone maintenance therapy is the cornerstone of treatment for heroin addiction. Hyperhidrosis is a common and often-overlooked side effect of methadone. Different medications, such as antihistamines and anticholinergic drugs, have been reported to be effective against opioid-induced sweating, but there is no standardized therapy. A 51-year-old patient under methadone maintenance therapy reported long-standing hyperhidrosis, which worsened each time the methadone dosage was increased. After substituting methadone with levomethadone, while maintaining equivalent dosages, the patient reported a stark reduction in sweating. Therefore, levomethadone could be a promising alternative for patients in methadone maintenance therapy who suffer from methadone-induced hyperhidrosis.
PMID:39910803 | DOI:10.1080/10550887.2024.2443696
Comparison of the effectiveness and safety between ramicotomy and sympathetic chain interruption in the treatment of primary hyperhidrosis: a meta-analysis
Clin Auton Res. 2025 Feb 5. doi: 10.1007/s10286-025-01115-x. Online ahead of print.
ABSTRACT
OBJECTIVE: This meta-analysis evaluates the effectiveness and safety of ramicotomy versus sympathetic chain interruption (SCI) in treating primary hyperhidrosis (PH).
METHODS: A comprehensive literature search was conducted across multiple databases, including PubMed, Embase, Web of Science, Ovid, Cochrane Library, CNKI, and Wanfang, covering studies from their inception through October 2024. A total of 10 studies involving 970 patients were included, with 504 patients undergoing ramicotomy and 466 receiving SCI.
RESULTS: The analysis revealed that patients undergoing ramicotomy experienced significantly lower rates of compensatory hyperhidrosis (CH) [odds ratio (OR) 0.41, 95% confidence interval (CI) 0.20-0.85, P = 0.02], severe CH (OR 0.17, 95% CI 0.06, 0.47, P < 0.001), and postoperative hand dryness (OR 0.10, 95% CI 0.01-0.72, P = 0.02), along with a higher recurrence rate (OR 4.03, 95% CI 2.38, 6.85, P < 0.001). No significant differences were observed in operative duration [mean difference (MD) = 0.19, 95% CI -18.23, 18.60, P = 0.98 > 0.05], length of hospital stay (MD = -0.08, 95% CI -0.19, 0.04, P = 0.20 > 0.05), total postoperative complications (OR 0.41, 95% CI 0.07, 2.34, P = 0.32 > 0.05), or surgical satisfaction (OR 0.93, 95% CI 0.45, 1.91, P = 0.83 > 0.05).
CONCLUSIONS: While ramicotomy results in lower incidences of CH and postoperative hand dryness, its higher recurrence rate suggests that its application should be cautious to manage PH effectively.
PMID:39907932 | DOI:10.1007/s10286-025-01115-x
The Creation of the Arabic Version of the Hyperhidrosis Quality of Life Index (HidroQoL) with Validation and Cross-Cultural Adaptation
Clin Cosmet Investig Dermatol. 2025 Jan 25;18:251-263. doi: 10.2147/CCID.S498688. eCollection 2025.
ABSTRACT
PURPOSE: Hyperhidrosis (HH) is characterized by excessive sweating, which can significantly affect quality of life. The Hyperhidrosis Quality of Life Index (HidroQoL©) is the latest tool that has been developed and validated for assessing the quality of life of patients with HH. Because of the absence of an Arabic version of the HidroQoL©, this research aimed to create, validate, and adapt the HidroQoL© into Arabic.
PATIENTS AND METHODS: A quantitative, analytical, cross-sectional study was conducted with HH patients followed up in dermatology or thoracic surgery clinics. We assessed the results reliability through internal consistency and reproducibility by assessing test‒retest reliability. For validity, we conducted an exploratory factor analysis with an interitem correlation matrix and a rotated component matrix.
RESULTS: A total of 167 participants were enrolled in this study; 61.1% were males, and 92.8% were Saudi. All 18 items of the HidroQoL©, including the daily life activities domain, psychosocial life domain, and whole HidroQoL©, had Cronbach’s alpha values above 0.7. The test-retest reliability assessment demonstrated strong reproducibility. The correlations between each item and the other 17 items of the scale were positive, ranging between 0.2 and 0.6, and the results of the components analysis suggested that the questionnaire has three domains. The correlation between the test-retest results of the HidroQoL© revealed a significant strong positive correlation (r=0.9, P˂0.001).
CONCLUSION: Our findings revealed excellent psychometric properties of the Arabic HidroQoL© in terms of structural and construct validity, internal consistency, and reproducibility. Proper utilization of the Arabic HidroQoL© adequately assesses the quality of life of those affected by HH.
PMID:39881852 | PMC:PMC11776515 | DOI:10.2147/CCID.S498688
Acute Hyperhidrosis: A Clue to Underlying Autonomic Dysfunction and a Rare Neurological Disorder
Cureus. 2024 Dec 25;16(12):e76387. doi: 10.7759/cureus.76387. eCollection 2024 Dec.
ABSTRACT
Acute hyperhidrosis is characterized by excessive sweating. In the absence of other symptoms, the symptoms of sweating alone are often benign and may be ignored by patients and clinicians. Rarely, hyperhidrosis may be a harbinger of an underlying severe disease. Autonomic nervous system dysfunction leading to hyperactivity of the sympathetic nervous system can result in excessive sweating. This case report is about a gentleman who presented with acute hyperhidrosis, a symptom of autonomic dysfunction, which turned out to be a relapse of anti-leucine-rich glioma-inactivated 1 (LGI1) antibody encephalitis. This case adds to the existing literature on cases of anti-LGI-1 encephalitis, a rare form of autoimmune encephalitis, and its varied clinical manifestations. It serves as a reminder to consider a wide range of differentials in patients who present with a seemingly nonspecific complaint such as excessive sweating.
PMID:39867015 | PMC:PMC11762238 | DOI:10.7759/cureus.76387